Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Non-cash Items (2022 - 2024)

Historic Non-cash Items for Stoke Therapeutics (STOK) over the last 3 years, with Q4 2024 value amounting to $20.4 million.

  • Stoke Therapeutics' Non-cash Items rose 14212.21% to $20.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $20.4 million, marking a year-over-year increase of 14212.21%. This contributed to the annual value of $20.4 million for FY2024, which is 14212.21% up from last year.
  • Stoke Therapeutics' Non-cash Items amounted to $20.4 million in Q4 2024, which was up 14212.21% from $8.4 million recorded in Q4 2023.
  • Stoke Therapeutics' 5-year Non-cash Items high stood at $20.6 million for Q4 2022, and its period low was $8.4 million during Q4 2023.
  • Its 3-year average for Non-cash Items is $16.5 million, with a median of $20.4 million in 2024.
  • As far as peak fluctuations go, Stoke Therapeutics' Non-cash Items plummeted by 5904.94% in 2023, and later soared by 14212.21% in 2024.
  • Quarter analysis of 3 years shows Stoke Therapeutics' Non-cash Items stood at $20.6 million in 2022, then plummeted by 59.05% to $8.4 million in 2023, then skyrocketed by 142.12% to $20.4 million in 2024.
  • Its Non-cash Items was $20.4 million in Q4 2024, compared to $8.4 million in Q4 2023 and $20.6 million in Q4 2022.